Pillar5 Pharma
Pillar5 Pharma is a Canadian CDMO specializing in sterile ophthalmic solutions manufacturing with market-leading Multi-Dose Preservative Free (MDPF) filling technology and solid dose tablet production for major multinational pharmaceutical customers. It is now a subsidiary of Prestige Consumer Healthcare.
- Company typePrivate
- Founded2009
- HeadquartersArnprior, Canada
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Pillar5 Pharma does
Pillar5 Pharma is a Canadian contract development and manufacturing organization (CDMO) founded in 2009 and headquartered in Arnprior, Ontario. The company serves pharmaceutical customers with two primary service lines: aseptic sterile ophthalmic solutions manufacturing — including market-leading Multi-Dose Preservative Free (MDPF) filling capabilities — and solid dose tablet production covering OTC, prescription, and animal health products across nervous system, respiratory, and other therapeutic categories. Production capacity stands at 30 million ophthalmic bottles per year and 255 million solid dose tablets per year, supported by 210+ employees including 50 specialists in Quality, Compliance, and technical transfer.
The business operates a B2B contract manufacturing model, generating revenue through manufacturing fees, technical services, and supply agreements with major multinational pharmaceutical clients. The facility has been Health Canada approved and has held an FDA Drug Establishment Registration for manufacturing and analytical testing for 14 years. Additional service offerings include analytical and microbiological testing, sterility assurance, and full validation and qualification support across the product development-to-manufacturing lifecycle. Pricing is not publicly disclosed and follows a quote-based B2B CDMO structure.
In December 2025, Prestige Consumer Healthcare (NYSE: PBH) completed its acquisition of Pillar5 Pharma to secure supply for eye care brands including Clear Eyes and TheraTears and to expand long-term production capacity. Prior to this acquisition, the company was associated with the ANJAC Health and Beauty group, which employed 3,000+ people across its broader industrial platform. Leadership comprises Dwight Gorham as President & CEO and Claude Germain as Chairman of the Board.
Pillar5 Pharma firmographics
Firmographics- Name
- Pillar5 Pharma
- Legal name
- Pillar5 Pharma Inc.
- Website
- https://pillar5pharma.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Pillar5 Pharma is a Canadian CDMO specializing in sterile ophthalmic solutions manufacturing with market-leading Multi-Dose Preservative Free (MDPF) filling technology and solid dose tablet production for major multinational pharmaceutical customers. It is now a subsidiary of Prestige Consumer Healthcare.
- Ownership category
- akta.pro rank
Pillar5 Pharma industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing (Sterile Ophthalmic CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Pillar5 Pharma is headquartered
LocationHeadquarters
- HQ city
- Arnprior
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Pillar5 Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Pillar5 Pharma operates as a CDMO providing contract manufacturing services for sterile ophthalmic solutions and solid dose tablets to pharmaceutical companies. Revenue is generated through manufacturing fees, technical services, and supply agreements with major pharma customers.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Pillar5 Pharma product offering
Product offeringCore offering
Pillar5 Pharma is a Canadian contract development and manufacturing organization (CDMO) that provides aseptic processing, filling, and packaging of sterile ophthalmic solutions, with leadership in Multi-Dose Preservative Free (MDPF) technology in North America. The company also manufactures solid dose tablets for OTC and prescription products across nervous system, respiratory, and animal health categories, supported by analytical, microbiological, validation, and qualification services.
Product overview
Pillar5 Pharma is a contract development and manufacturing organization (CDMO) offering two primary service lines: sterile ophthalmic solutions manufacturing with leading Multi-Dose Preservative Free (MDPF) technology, and solid dose tablet production for OTC and prescription pharmaceuticals. The company operates as a full-service provider supporting pharmaceutical customers from product development through manufacturing, with capabilities in aseptic processing, filling, packaging, and validation services.
Differentiator
Problem solved
Functional benefit
Products and services
- Sterile Ophthalmic Solutions Manufacturing
Quantifiable outcome
- 100% of ANJAC innovations featuring at least one sustainable objective by 2026
- +2 more outcomes
Companies that use Pillar5 Pharma
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Pillar5 Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Pillar5 Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Prestige Consumer HealthcarecorePrestige Consumer Healthcare acquired Pillar5 Pharma to enhance supply capabilities in the eye care category and expand long-term production capacity. The acquisition adds MDPF manufacturing expertise to Prestige Consumer's existing eye care brands including Clear Eyes and TheraTears. Pillar5 Pharma now operates as a subsidiary under Prestige Consumer Healthcare Inc.
Scale indicators5 records
Recent moves4 records
Expansion highlights5 records
Pillar5 Pharma competitors and assessment
Company assessmentBroad incumbents
- Recipharm: European-headquartered CDMO with sterile liquids, semi-solids, and solid dose manufacturing; competes for the same types of contract sterile ophthalmic and oral dose work as Pillar5.
- PCI Pharma Services: Large global CDMO offering sterile fill-finish, ophthalmic manufacturing, and solid dose services; overlaps with Pillar5 but at broader scale and across multiple therapeutic areas.
- Aenova Group: European CDMO with solid dose, semi-solid, and sterile liquid capabilities including ophthalmic; a comparable incumbent serving multinational pharma with similar dosage forms.
- Catalent: One of the largest global CDMOs with extensive sterile fill-finish and oral solid dose capabilities including ophthalmic programs; a broader incumbent in Pillar5's product categories.
- Bora Pharmaceuticals: Global CDMO offering sterile, ophthalmic, and oral solid dose services following acquisitions of Upsher-Smith and generics manufacturing assets; competes in Pillar5's core dosage forms.
- Curia (formerly AMRI): Integrated CDMO with sterile fill-finish and oral solid dose capabilities serving pharmaceutical clients; comparable as a full-service contract manufacturer across overlapping dosage forms with Pillar5.
Direct peers
- Grand River Aseptic Manufacturing (GRAM): FDA-inspected sterile injectable CDMO with ophthalmic and small-batch aseptic filling capabilities; competes for the same preservative-free and sterile ophthalmic contract manufacturing work as Pillar5.
- Renaissance Lakewood (RLS): Sterile liquid and ophthalmic contract manufacturer offering aseptic filling of ophthalmics and other sterile solutions; overlapping directly with Pillar5's sterile ophthalmic and MDPF business.
- Woodstock Sterile Solutions: U.S.-based sterile contract manufacturer specializing in sterile ophthalmic and injectable liquids; the most directly comparable pure-play ophthalmic sterile CDMO to Pillar5's MDPF and aseptic filling services.
- CoreRx: Sterile and non-sterile CDMO with capabilities in ophthalmic, liquid, and semi-solid manufacturing; comparable in scale and service mix to Pillar5's ophthalmic and solid dose lines.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Pillar5 Pharma social profiles
Digital presencePillar5 Pharma compliance and trust
Trust signalCompliance2 records
Pillar5 Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pillar5 Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Pillar5 Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pillar5 Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pillar5 Pharma
What does Pillar5 Pharma do?
Pillar5 Pharma is a Canadian contract development and manufacturing organization (CDMO) that provides aseptic processing, filling, and packaging of sterile ophthalmic solutions, with leadership in Multi-Dose Preservative Free (MDPF) technology in North America. The company also manufactures solid dose tablets for OTC and prescription products across nervous system, respiratory, and animal health categories, supported by analytical, microbiological, validation, and qualification services.
Is Pillar5 Pharma a public or private company?
Pillar5 Pharma is a private company. It is classified as corporate owned and is currently acquired.
When was Pillar5 Pharma founded?
Pillar5 Pharma was founded in 2009. It employs 101 to 250 people.
Where is Pillar5 Pharma based?
Pillar5 Pharma is headquartered in Arnprior, Canada, in the North America region.
How does Pillar5 Pharma make money?
One revenue line is on record: contract Manufacturing Services.
Who are Pillar5 Pharma's main competitors?
Broad incumbents on record are Recipharm, PCI Pharma Services, Aenova Group, Catalent, Bora Pharmaceuticals and Curia (formerly AMRI). Direct peers are Grand River Aseptic Manufacturing (GRAM), Renaissance Lakewood (RLS), Woodstock Sterile Solutions and CoreRx.
Does Pillar5 Pharma have an API?
No public API is recorded for Pillar5 Pharma.
What industry is Pillar5 Pharma in?
Pillar5 Pharma's product category is Pharmaceutical Contract Manufacturing (Sterile Ophthalmic CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.